{"id":"NCT00635648","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)","officialTitle":"A Non-comparative, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate (MK-0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2011-05","completion":"2011-05","firstPosted":"2008-03-14","resultsPosted":"2012-05-28","lastUpdate":"2017-03-24"},"enrollment":63,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fungal Infection"],"interventions":[{"type":"DRUG","name":"caspofungin acetate","otherNames":["MK0991","CancidasÂ®"]}],"arms":[{"label":"Caspofungin 50 mg Intravenous (IV)","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety, tolerability, and efficacy of caspofungin for the treatment of esophageal candidiasis and invasive candidiasis to support the registration of caspofungin for these indications in China.","primaryOutcome":{"measure":"Number of Participants With One or More Drug-related Serious Adverse Events","timeFrame":"First dose of study drug through 14 days post therapy (maximum 28 days of study drug for esophageal candidiasis, 60 days for invasive candidiasis; mean treatment duration of 14 days)","effectByArm":[{"arm":"Caspofungin 50 mg q.d. IV","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":63},"commonTop":["Blood Potassium Decreased","Alanine Aminotransferase Increased","Aspartate Aminotransferase Increased","Blood Bilirubin Increased","Blood Creatinine Increased"]}}